{
    "patient": {
        "Name": "Micheal Baker",
        "DateOfBirth": "1964-04-29",
        "Sex": "Female",
        "Diagnosis": "Lymphoma",
        "BodyPart": "Colorectal",
        "Physician": "Dr. Joshua Villa",
        "TreatingInstitution": "Contreras PLC"
    },
    "specimen": {
        "Tumor specimen": {
            "source": "Colorectal",
            "CollectedDate": "2023-11-28",
            "ReceivedDate": "2023-12-02",
            "TumorPercentage": "92%"
        },
        "Normal specimen": {
            "source": "Blood",
            "CollectedDate": "2023-12-02",
            "ReceivedDate": "2023-12-02"
        }
    },
    "genomic variants": {
        "Somatic - Potentially Actionable": [
            {
                "Gene": "AKT1",
                "DNA Alteration": "c.49G>A",
                "GeneMutation": "p.E17K Stopgain-LOF",
                "VariantAlleleFraction": "39.66%"
            }
        ],
        "Somatic - Biologically Relevant": [
            {
                "Gene": "IKZF1",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.E17K Nonsense-LOF",
                "VariantAlleleFraction": "26.49%"
            },
            {
                "Gene": "PIK3CA",
                "DNA Alteration": "c.1635G>T",
                "GeneMutation": "p.H1047X Frameshift-LOF",
                "VariantAlleleFraction": "3.5%"
            }
        ],
        "Germline - Pathogenic": [],
        "Pertinent Negatives": [
            "HDAC2",
            "PIK3CA",
            "PDGFRA"
        ]
    },
    "immunotherapy markers": [
        {
            "marker_name": "Tumor Mutational Burden",
            "TmbValue": "25 m/Mb",
            "Tmbpercentile": "37%",
            "Status type": "Microsatellite Instability Status",
            "statusvalue": "Equivocal"
        }
    ],
    "FDA-Approved Therapies": {
        "Current Diagnosis": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ],
        "Other Indications": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ]
    },
    "Additional Indicators": [
        {
            "description": "Unfavorable Prognosis",
            "therapy": "NCCN, Consensus, Non-Small Cell Lung Cancer",
            "mutation": "KRASp.G12C Gain-of-function"
        }
    ],
    "Clinical trials": [
        {
            "description": "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer ",
            "phase": "Phase 2",
            "mutations": [
                "KRAS"
            ]
        },
        {
            "description": "A Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
            "phase": "Phase 1/2",
            "mutations": [
                "KRAS",
                "STK11"
            ]
        },
        {
            "description": "First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. (NCT04471415)",
            "phase": "Phase 1/2",
            "mutations": [
                "NFE2L2",
                "STK11"
            ]
        }
    ],
    "variants of unknown significance": {
        "Somatic": [
            {
                "Gene": "CHEK2",
                "DNA Alteration": "c.1283C>T",
                "GeneMutation": "p.S428F Spliceregionvariant-LOF",
                "VariantAlleleFraction": "21.2%"
            },
            {
                "Gene": "PRKCA",
                "DNA Alteration": "c.1387G>C",
                "GeneMutation": "p.D463H Spliceregionvariant-GOF",
                "VariantAlleleFraction": "19.37%"
            },
            {
                "Gene": "RNF43",
                "DNA Alteration": "c.954G>T",
                "GeneMutation": "p.P154L Frameshift-LOF",
                "VariantAlleleFraction": "1.85%"
            },
            {
                "Gene": "CSF3R",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.G751A Spliceregionvariant-LOF",
                "VariantAlleleFraction": "5.63%"
            },
            {
                "Gene": "MUTYH",
                "DNA Alteration": "c.1014G>C",
                "GeneMutation": "p.Q338H Frameshift-GOF",
                "VariantAlleleFraction": "6.94%"
            },
            {
                "Gene": "RNF43",
                "DNA Alteration": "c.420C>G",
                "GeneMutation": "p.E318D Nonsense-GOF",
                "VariantAlleleFraction": "1.17%"
            },
            {
                "Gene": "ERCC2",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.F332V Spliceregionvariant-GOF",
                "VariantAlleleFraction": "4.21%"
            },
            {
                "Gene": "BRCA1",
                "DNA Alteration": "c.68_69delAG",
                "GeneMutation": "p.E23Vfs*17 Spliceregionvariant-GOF",
                "VariantAlleleFraction": "3.49%"
            },
            {
                "Gene": "B2M",
                "DNA Alteration": "c.2T>G",
                "GeneMutation": "p.M1R Spliceregionvariant-GOF",
                "VariantAlleleFraction": "9.45%"
            },
            {
                "Gene": "PRKCA",
                "DNA Alteration": "c.1387G>C",
                "GeneMutation": "p.D463H Spliceregionvariant-GOF",
                "VariantAlleleFraction": "8.16%"
            }
        ],
        "Germline": []
    },
    "low coverage regions": [
        "BLM"
    ],
    "genomic variants details": {
        "Somatic Variant Details - Potentially Actionable": [
            {
                "Gene": "AKT1",
                "DNA Alteration": "c.49G>A",
                "GeneMutation": "p.E17K Stopgain-LOF",
                "description": "PTEN encodes a phosphatase that acts as a tumor suppressor by negatively regulating the PI3K-AKT-mTOR pathway. Loss of function mutations, copy number loss, and underexpression of PTEN are associated with cancer progression.",
                "VariantAlleleFraction": "39.66%"
            }
        ],
        "Somatic Variant Details - Biologically Relevant": [
            {
                "Gene": "IKZF1",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.E17K Nonsense-LOF",
                "description": "RBM10 encodes a protein that contains a RNA-binding motif and interacts with RNA homopolymers, and is thought to function in regulating alternative splicing. Loss of function mutations and copy number loss of RBM10 are associated with cancer progression.",
                "VariantAlleleFraction": "26.49%"
            },
            {
                "Gene": "PIK3CA",
                "DNA Alteration": "c.1635G>T",
                "GeneMutation": "p.H1047X Frameshift-LOF",
                "description": "FAT1 encodes a transmembrane protein involved in tumor suppressor signaling. FAT1 protein can regulate transcriptional activity by sequestering beta-catenin, thereby preventing it from entering the nucleus. Loss of function mutations and copy number loss of FAT1 are associated with cancer progression.",
                "VariantAlleleFraction": "3.5%"
            }
        ]
    },
    "clinical history": {
        "Date": "2023-11-27"
    },
    "other": {
        "ReportId": "9716",
        "ReportDate": "2023-11-29",
        "SignedBy": "Joshua Villa",
        "Supervisor": "Dr. Kimberly Boyd"
    }
}